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Background/aim: To explore the potential of the circulating plasma miRNA-21 as an early detection biomarker by comparing earlystage breast cancer (BG) and healthy control (HG) in Indonesian population.
Materials and methods: The enlisted patients were 26 adult female early-stage breast cancer patients (stage 1A, 1B, 2A, and 2B) of
Airlangga University Hospital from August 2019 to October 2019. Sixteen volunteers were recruited as matching healthy subjects.
MiRNA-21 expression was quantified by plasma qRT-PCR. Data analysis performed using IBM SPSS Statistics v.24 (IBM Corp.,
Armonk, NY, USA). MiRNA-21 cut-off, sensitivity, and specificity were analyzed using receiver operating characteristic (ROC) curve.
Results: The study included 26 BG and 16 HG subjects. The miRNA-21 expression in BG group was 3.933 (1.181-11.794) and 0.905
(0.164-4.532) in HG group (4.34 folds; P = 0.001), with 1.66 cut-off (92.3% sensitivity; 81.2% specificity). MiRNA-21 expression separated
analysis in HG showed a 0.578 times lower expression in menopause subjects [0.651 (0.164-0.414)], compared to premenopause ones
[(1.123 (0.758 - 4.532); P = 0.031]. Yet, in BG group, 1.729 times higher miRNA-21 expression was observed in menopause subjects
(6.021 ± 3.583), compared to premenopause ones (3.500 ± 1.517; P = 0.022).
Conclusion: Circulating miRNA-21 expression is a potential biomarker for early detection of breast cancer and might act as a breast
cancer risk predictor.
Key words: Biomarkers, breast neoplasms, diagnosis, human plasma, miRNA-21

1. Introduction
Breast cancer is the malignancy of the breast tissues
originating from uncontrolled proliferation of breast
ductal and lobular epithelial cells[1]. Breast cancer is
known as the second most prevalent malignancy in
women worldwide [2]. The trend of breast cancer and
overall cancer incidence has also showed an increase in
developing countries1. Particularly in Indonesia, breast
cancer is placed as the most prevalent cancer. In fact, more
than 80% of breast cancer cases is diagnosed in advanced
stage2. Triple test diagnostic approach (simultaneous
physical examination, radiological examination, and
histopathological examination) for determining the

malignancy of breast tissues is an important procedure.
However, this approach still has its limitations, especially
in early detection of breast cancer [3]. Histopathology
examination is the gold standard of breast cancer
diagnostic, yet this examination is constrained by its
invasiveness [4]. Radiology examination exposes the
patient to radiation, with a disadvantage in the young
patient [5], and the breast ultrasound examination could
be operator dependent [6].
Besides the triple test and ultrasound examination,
several blood tumor biomarkers are routinely used
in medical practice with their specific roles. Tumor
markers, such as carbohydrate antigen 15-3 (CA 15-3)
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and carcinoembryonic antigen (CEA), provide clinicians
with information about cancer therapeutic response in
advanced cancer stage and lack of practical information in
early-stage breast cancer [7–9]. Besides, circulating blood
tumor markers also showed relatively poor sensitivity and
specificity [8,9].
MicroRNA (miRNA) is a small class noncoding RNA
with 22-25 lengths of nucleotides that are present in the
body fluid and tissues [10]. MiRNA plays an important
role in gene expression as a critical gene regulator through
epigenetic mechanism [10]. MiRNA acts as a silencer of
messenger RNA (mRNA) through mRNA degradation,
which impacts mRNA translation and expression. This
mechanism affects the downstream cellular process,
including cell maturation, cell differentiation, cell invasion,
metastasis, and apoptosis [10]. Dysregulation of miRNArelated processes by mutation, deletion, translocation, and
an increase or decrease of expression eventually could
impair cell metabolism [11]. Several specific miRNAs
suppress oncoproteins expression in normal cells.
Nonetheless, increasing expression of different particular
miRNA was also noticed in malignancy [11].
In breast cancer, there are several miRNAs, which
tend to be upregulated (miRNA-21, miRNA-10b, miRNA125b, miRNA-145, miRNA-155, and miRNA-191) and
downregulated (miRNA-7, miRNA-17p, miRNA-27b,
miRNA-143, dan miRNA-139) [12,13]. In particular,
miRNA-21 is known to be characterized in breast cancer
[10,14,15].
MiRNA-21 is an intron miRNA, coded in chromosome
17q23.1. MiRNA-21 expression affected cell proliferation,
cell invasion, metastasis, and apoptosis [10]. MiRNA-21
target involves a group of tumor suppressor genes,
including TPM1, TIMP3, RECK, p53 network, Cdc25A,
PTEN, PDCD4, and Maspin [10]. MiRNA-21 could trigger
breast cell proliferation and transformation by repressing
the translation of tumor suppressor gene PDCD4, which is
involved in apoptosis regulator [10,16].
MiRNA-21 expression could be detected in the tumor
tissues, serum, plasma, and cerebrospinal fluid [4].
Expression of miRNA-21 in breast cancer tissues showed
variability; however, miRNA-21 expression in blood
circulation tends to be more stable [4,17].
High expression of circulating miRNA-21 might be
an indicator of breast cancer [18]. Several studies evaluate
the cut-off point of miRNA-21 resulting in variability of
cut-off point, specificity, and sensitivity for miRNA-21
expression [8,19,20]. Despite the variability, studies of
miRNA-21 expression overall show promising sensitivity
and specificity for detecting breast cancer. Circulating
miRNA-21 expression levels in Indonesian breast cancer
patients have never been assessed before. Hence, it is
needed to assess miRNA-21 potential as a breast cancer

early biomarker in Indonesian population, by comparing
circulating expression of miRNA-21 in early-stage breast
cancer patients compared to a healthy population.
2. Materials and methods
2.1. Breast cancer patients
The patients who were later defined as breast cancer group
(BG) (n = 26) were recruited from the Hematology-Medical
Oncology policlinic, Airlangga University Hospital,
Surabaya, East Java, Indonesia, from among breast cancer
outpatients between August 2019 and October 2019.
The breast cancer diagnosis was confirmed by triple test
approach. The inclusion criteria were as follows: female
patients, more than 18 years old, early-stage breast cancer
(Stage 1A, 1B, 2A, and 2B). The patients who had other
malignancies were excluded from the study. Healthy
subjects were recruited from age-matched and menstrual
status-matched healthy volunteers. The entire healthy
subject group has been proven to be healthy by physical
examination. The healthy subjects were later defined
as healthy group (HG). The subjects gave their written
informed consent before participating in this study.
This study has been reviewed for its ethical eligibility by
Airlangga University Hospital Bioethical Committee,
which was proven by Ethical Clearance Document No.
164/KEP/2019. Patient identity and data (age, sex, and
menstrual status) were obtained from medical records and
anamnesis.
2.2. Plasma preparation
Blood sample collection was performed in HematologyMedical Oncology polyclinic, Airlangga University
Hospital, Surabaya, East Java, Indonesia. Blood sample
collection was performed after early-stage breast cancer
diagnosis was confirmed and neoadjuvant chemotherapy
procedure with mixed patient history of curative surgery.
The blood sample was drawn from peripheral blood by
venipuncture and needle aspiration of a 5-mL peripheral
blood. The blood was collected into BD Vacutainer®
EDTA tube (Becton, Dickinson and Company, Plymouth,
UK). Plasma isolation was obtained by performing
centrifugation of the 5-mL blood sample (1900 G; 10 min).
The supernatant was collected without disturbing buffycoat layer and recentrifuged (1900 G; 10 min) to obtain
clear plasma. Blood plasma sample has advantages over
serum sample materials, due to the presence of minimal
hemolysis as a confounding variable [21].
2.3. RNA extraction
Total plasma RNA extraction was conducted using
Qiagen miRNeasy serum/plasma kit (Cat: 217184, Lot:
163011798, Qiagen, Hilden, Germany) according to the
protocol provided by kit manufacture. Total RNA content
was measured using NanoDrop (Thermo Fisher Scientific
Inc., Waltham, MA, USA).
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2.4. cDNA (complementary DNA) synthesis
Total isolated RNA from plasma was then transferred and
underwent reverse transcription for producing cDNA.
Reverse transcription was carried out using TaqMan
MicroRNA reverse transcription kit (Cat.4366596,
Lot 00783142, Applied Biosystems, Carlsbad, USA) by
mixing 3 μl of RT primer and 5 μl RNA sample (1-10
ng RNA) with 7μl of reverse transcription reaction mix.
The thermal cycle setting that used was 16 °C for 30 min,
42 °C for 30 min, and. 85 °C for 5 min. The synthesized
cDNA was then stored at −20 °C before entering the
quantitative real-time polymerase chain reaction (qRTPCR). The primers used as endogenous control were
Hsa-miR-21-3p (miRNA-21) and Hsa-miR-16-5p
(miRNA-16).
2.5. MiRNA-21 expression quantification
qRT-PCR from cDNA was performed using TaqMan
MicroRNA assay kit (Applied Biosystems, California,
USA) for miRNA-21, TaqMan endogenous control assay
for miRNA-16 (Applied Biosystems, Waltham, MA,
USA), and TaqMan Universal PCR master mix II, No
UNG (Applied Biosystems, Waltham, USA) according
to the protocol provided by respective manufacture.
qRT-PCR started by mixing cDNA with PCR reaction
mix. The thermal cycle setting for qRT-PCR was 95
°C for 10 min, 95 °C for 15 s (40 cycles), and 60 °C for
60 s. Sample banking and analysis were performed in
Prodia Clinical Laboratory Jakarta. Relative miRNA-21
expression (2-ΔΔCt) was quantified through automatic
quantification with miRNA-16 as an endogenous control.
This simultaneous detection of miRNA-21 coupled with
miRNA-16 as an endogenous control in the qRT-PCR
improves the precision of miRNA-21 as a biomarker
[21–23].
2.6. Data analysis
Data normality was assessed through Shapiro-Wilk test.
Subject age was analyzed using independent t-test, and
subjects’ menstrual status matching was assessed using
Fisher’s exact test. MiRNA-21 expression comparison
between HG and BG was analyzed using Mann-Whitney
test. Analysis of miRNA-21 expression between HG and
1A, 1B, 2A, and 2B stage BG was performed utilizing
Kruskall-Wallis test. Further analysis of miRNA-21
expression based on menstrual status separated for the
entire subject and HG was performed using MannWhitney test, whereas independent t-test was used for
assessing BG. MiRNA-21 cut-off point, sensitivity, and
specificity were obtained through receiver operating
characteristic (ROC) curve analysis. IBM SPSS Statistics
v.24.0 (IBM Corp.) software was used for performing the
entire statistical analysis. Statistical significance was set
at the 0.05 probability level (P < 0.05).
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3. Results
3.1. Subject characteristics
The mean ages of the HG and BG in this study were 49.750
± 10.428 and 50.000 ± 10.987, respectively (P = 0.883).
Menstrual status evaluation also showed an insignificant
difference between both groups (P = 0.589). Indicated an
age and menstrual status-matched group (Table 1).
3.2. Circulating miRNA-21 expression comparison
between HG and BG
There is a significant increase in miRNA-21 expression
in breast cancer patients compared to healthy control
subjects, indicated by the 4.364-fold increase in median
miRNA-21 expression from HG compared to BG, 0.901
(0.164-4.364) and 3.933 (1.181-11.794), respectively (P =
0.001), based on Mann-Whitney test (Table 2). Evaluation
of the miRNA-21 comparison in the specific breast cancer
stage based on the Kruskall-Wallis test suggested that
there is a significant difference in miRNA-21 expression
across healthy control group (HG) and breast cancer
subject group (stage 1A, 1B, 2A, and 2B BG) (P = 0.006)
(Figure 1).
3.3. Circulating miRNA-21 expression based on
menstrual status
Further analysis of miRNA-21 expression, in both HG
and BG separately, revealed HG miRNA-21 expression
of 1.123 (0.758-4.532) for premenopause subjects and
0.651 (0.164-0.414) for menopause subjects (0.578 times
decrease, P = 0.031). On the contrary, in BG, we observed
1.720 times more miRNA-21 expression in premenopause
subject (3.500 ± 1.517) and miRNA-21 expression of 6.021
± 3.583 for the menopause subjects. However, miRNA-21
expression analysis on the entire subjects revealed an
insignificant difference (P = 0.929) (Table 3).
3.4. Circulating miRNA-21 expression in correlation
with age
There was an insignificant correlation between subjects’
ages with miRNA-21 expression, whereas the correlation
was measured in the entire subjects (P = 0.512), in HG (P
= 0.166), or BG (P = 0.057).
3.5. Circulating miRNA-21 expression cut-off value,
sensitivity, and specificity
The ROC (receiver operating characteristic) curve analysis
in this study reveals circulating plasma miRNA-21
expression cut-off value as 1.86, with 92.3% area under the
ROC curve (ROC-AUC) (95% confidence interval: 83.4%100%). ROC curve evaluation yielded 92.3% sensitivity
and 81.2% specificity (Figure 2).
4. Discussion
In our study, we observed that the mean age of HG was
50.000 ± 10.428 and BG was 50.000 ± 10.987 (P = 0.895).
Also, the menstrual status in both groups showed an
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Table 1. Subject characteristics.
Healthy control group
(n = 16)

Breast cancer group
(n = 26)

P

20-29

0

1

n.a

30-39

3

3

n.a

40-49

7

10

n.a

50-59

2

7

n.a

60-69

3

3

n.a

70-79

1

2

n.a

Age mean (years)

49.750 ± 10.428a

50.000 ± 10.987a

0.883b

Premenopause

56.25% (n = 9)

57.69% (n = 15)

Menopause

43.75% (n = 7)

42.31% (n = 11)

Stage 1A

-

15.38% (n=4)

n.a

Stage 2B

-

3.85% (n=1)

n.a

Variable
Age distribution (years)

Menstrual status
0.589c

Breast cancer staging

Stage 2A

-

34.62% (n=9)

n.a

Stage 2B

-

46.15% (n=12)

n.a

The results are described as mean ± standard deviation (SD).
P-value is reported based on the analysis of independent sample t-test (95% CI).
c
P-value is reported based on the analysis of Fisher’s exact test (95% CI).
a

b

Table 2. Circulating miRNA-21 expression comparison between BG and HG.
Variable

Breast cancer
subjects (n = 26)

Healthy control
subjects (n = 16)

miRNA-21
expression change

P

miRNA-21 expression (2-ΔΔCt)

3.933
(1.181-11.794)a

0.901
(0.164-4.532)a

4.364
times increase

0.001b

The results are described as median (min-max).
P-value is reported based on the analysis of Mann-Whitney U test (95% CI).

a

b

insignificant difference (P = 0.589). This result suggested
that this study could represent a population of adult female
patients. Therefore, further analysis of other parameters
between both groups could be performed with a relatively
minimalized bias [20].
In this study, the median value of miRNA-21 circulating
plasma expression in the breast cancer group was 3.933
(1.181 - 11.794) while in the healthy control group it was
0.901 (0.164-4.532), which indicated that overall circulating
miRNA-21 expression in the BG tends to be greater than
HG with a median increase of 4.364 times. This finding is
consistent with a previous study carried out by Gao et.al..
In their study, healthy group’s miRNA-21 expression was
9.1, and it was 30.82 for the breast cancer groups (3.39
folds increase) [8]. Another study also reported similar

results of 3.05 HG mean circulating miRNA-21 expression
and 6.88 for BG (2.25 times increase) [24]. The variability
of miRNA-21 based on the previous study might be caused
by the variability of detection kit that was used, patient
demographic characteristics, and differences in the sample
population, including genetic and epigenetic variances. The
significant difference in miRNA-21 expression across HG
and BG for each stage (stage 1A, 1B, 2A, and 2B) suggests
that each group showed a significant difference; however,
evaluation of a single group breast cancer progression
could not be generalized as the sample does not tend to
be evenly distributed, especially in the 1B stage breast
cancer group which was composed only of 1 patient’s data.
Hence, further evaluation for each group through post hoc
analysis is required.
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Figure 1. MiRNA-21 expression in 1A, 1B, 2A, and 2B stage breast cancer patients
(BG) compared to healthy control subjects (HG). Note: White dots indicate circulating
miRNA-21 expression data, black line indicates circulating miRNA-21 expression median.
Table 3. Circulating miRNA-21 expression comparison between premenopause and menopause subjects.
Variable

miRNA-21
expression
(2-ΔΔCt)

Groups

Premenopause

Menopause

miRNA-21
expression change

P

Healthy control
subjects (n = 16)

1.123
(0.758-4.532)a

0.651
(0.164-0.414)a

0.578 times decrease

0.031c

Breast cancer
subjects (n = 26)

3.500 ± 1.517b

6.021 ± 3.583b

1.720 times increase

0.022d

Total (n = 42)

2.594
(0.758-6.916)a

2.912
(0.164-11.794)a

1.123 times increase

0.929c

The results are described as median (min-max).
The results are described as mean ± standard deviation (SD).
c
P-value is reported based on the analysis of Mann-Whitney U test (95% CI).
d
P-value is reported based on the analysis of independent sample t-test (95% CI).
a

b

Additionally, we assess miRNA-21 expression difference
between premenopause and menopause subjects through
total subject analysis, HG, and BG analysis. There is an
insignificant circulating miRNA-21 expression difference
between premenopause and menopause women across the
entire subjects. However, this result might be caused by a
conflicting miRNA-21 expression tendency in HG and BG
as our study reported.
In BG circulating miRNA-21 tends to be higher in
menopause subjects, which was in line with previous
findings [25]. Separated analysis on HG revealed a
significant decrease in circulating miRNA-21 expression
in menopause women. This finding might indicate that
circulating miRNA-21 expression tends to decrease
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after menopause in normal settings. However, in breast
cancer cases due to the various circumstances, circulating
miRNA-21 expression is increased and contributes to
oncogenesis [10,26]. Hence, larger studies that objectively
confirm our finding are still needed. Further 2-time
point circulating miRNA-21 evaluation before and
after menopause study should be performed for further
understanding of its role in breast cancer occurrence and
determining its usage in diagnostic.
The menopausal and premenopausal miRNA-21 level
difference could be caused by several mechanisms that
are related to aging and hormonal metabolism changes.
Menopause substantially changes women’s hormonal
metabolism, especially in the metabolism of estrogen.
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Figure 2. MiRNA-21 expression ROC curve.

Before menopause, estrogen production is mainly
coordinated by hypothalamus-pituitary-ovarian axis
with estradiol as the most prominent estrogen produced.
However, after menopause, the estrogen main producer
is switched to adipose tissues with estrone as the major
estrogen hormone in postmenopausal women [27]. These
metabolic changes could eventually provide a distinct organ
response towards different estrogen dominancy stimuli.
It is reported that estrone and estradiol trigger distinct
transcriptome in breast cancer. Estrone exhibits NFκBrelated inflammatory cytokines genes induction, whereas
estradiol suppressed this mechanism in breast tissues.
Moreover, in vivo study in the ER-positive breast cancer
model showed that estrone promotes tumor progression,
inflammation response, and increases ALDH1 activity as a
breast cancer stem cell marker that suggests a worse breast
cancer prognosis [28].
Furthermore, a distinctive signaling complex
of miRNA-21 and NFκB in a specific type of cells
was also identified. In epithelial cells, miRNA-21
downregulate PTEN, activate AKT, and upregulate NFκB with a possibility to exist as a positive feedback loop
as demonstrated in a nontumorigenic human mammary
cell line (MCF-10A) and might be present in various
breast cancer cells [29]. Nevertheless, as our study utilized
circulating plasma miRNA-21 level, the balance between
miRNA-21 and NF-κB signaling might be affected by other
types of cells besides breast epithelial cells that possessed
discrete miRNA-21 and NF-κB signaling cascades. This
model might be explained by the opposite miRNA-21

and NF-κB interaction in the LPS-stimulated macrophage
that exhibits PDCD4 downregulation, followed by NFκB downregulation as a negative feedback loop [30].
Therefore, based on the previous findings, it is suggested
that our findings of the lower miRNA-21 expression level
in postmenopausal healthy subjects and its counterpart
might be linked to miRNA-21 and NF-κB feedback loop
balance in various cells without overlooking human
body as a whole entity. Additionally, a further extent of
miRNA-21 and NF-κB feedback loop balance should
be performed for understanding a bigger picture of this
phenomenon.
Evaluation of hormonal aspects should also be
explored as menstrual status is connected with hormonal
exposure. A previous study reported that the miRNA-21
tends to be correlated with the triple-negative breast
cancer intrinsic subtype [26]. Yet, another study stated that
there is an insignificant miRNA-21 expression difference
in the absence and presence of progesterone receptor (PR),
estrogen receptor (ER), and human epidermal growth
factor receptor-2 (HER2) [25].
Correlation between miRNA-21 and age in total
subject, HG, and BG showed no significant correlation.
These results are in line with the prior study of miRNA-21
correlation [24]. An insignificant correlation between
miRNA-21 level and age might indicate that circulating
miRNA-21 expression is not related to aging mechanism.
The ROC curve yields circulating plasma miRNA-21
expression cut-off value of 1.86 with an area under the ROC
curve (ROC-AUC) of 92.3% (95% confidence interval:
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83.4%-100%), the sensitivity of 92.3%, and specificity
of 81.2%. These results are consistent with the previous
study by Gao et.al. which reported 92.9% ROC - AUC,
with a difference in overall sensitivity (82.6%), and overall
specificity (87.3%). This study also states that miRNA-21
showed a higher sensitivity for detecting stage 1 breast
cancer (92.24%) [8]. Another study by Wang and Zhang
reported a lower ROC - AUC (88%), specificity (87.7%),
and sensitivity (80%) with a higher 4.58 cut-off value [24].
A study by Mar-Aguilar et. al. also reported decent ROCAUC (95%), specificity (80%), and sensitivity (94.40%),
with 6.48 as a cut-off value [19]. The difference between the
results of diagnostic values with

some previous studies in
cut-off values, sensitivity, and specificity might occur due
to the differences in the subjects’ genetic makeup, breast
cancer stages, sample materials, RNA extraction methods,
qRT-PCR analysis methods, and other confounding
factors.
Limitation of this study includes the following: limited
total subjects (the limitation was caused by subject
recruitment timeframe from August 2019 to October
2019), uneven distribution of each breast cancer stage
subject representation (1A, 1B, 2A, and 2B) with only
one subject included in 1B group absence of breast cancer
subtype data, absence of BG estrogen receptor status,

absence of serum estrogen level data, hormonal-affecting
medication data, contraception data, and mixed subject
history of curative surgery.
In conclusion, the expression of circulating plasma
miRNA-21 in the early stage of breast cancer is increased
compared to healthy control subjects. Therefore,
suggesting that the detection of circulating miRNA-21
expression might serve as a potential diagnostic tool
for detecting early-stage breast cancer. Moreover, based
on the tendency of increasing circulating miRNA-21
expression in menopause breast cancer patients compared
to premenopause breast cancer patients with a contrary
finding in HG, it is suggested that miRNA-21 might serve
as a breast cancer risk predictor.
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